Pharmaceutical intermediates
Bosutinib Intermediates
2 pharmaceutical intermediates for Bosutinib. Indication: Chronic myeloid leukemia; Chronic myelomonocytic leukemia; Myeloid leukemia acceleration; Blast cell crisis.
About Bosutinib
- Originator
- Pfizer Inc
- Indication
- Chronic myeloid leukemia; Chronic myelomonocytic leukemia; Myeloid leukemia acceleration; Blast cell crisis
- Approved Date
- 09/04/2012
- DS/DP
- 12/11/2025
Available intermediates
2 intermediates currently listed for Bosutinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Chloro-7-(3-chloropropoxy)-6-methoxyquinoline -3-carbonitrile | 214470-68-5 | / | / |
| 2,4-Dichloro-5-methoxyaniline | 98446-49-2 | / | / |
Building toward Bosutinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →